Compare Jumia Technologies AG - ADR (JMIA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Johnson & Johnson — how do they compare? Jumia Technologies AG - ADR trades at $6.31 (market cap $783.99M), while Johnson & Johnson trades at $249.15 (market cap $598.96B). The key difference: Johnson & Johnson is far larger — about 764× Jumia Technologies AG - ADR's market cap, and Johnson & Johnson pays a 2.15% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | JNJ | |
|---|---|---|
Market Cap | $783.99M | $598.96B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $267.24 |
52-Week Low | $4.45 | $164.36 |
Enterprise Value | $731.09M | $631.90B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.36, down 2.15% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth to $188.93M in 2025 and narrowing losses, targeting 2027 profitability. Analyst sentiment remains positive with 71% buy ratings despite recent earnings misses. Recent news highlights strong Q1 2026 performance and strategic board appointments.
JMIA presents a high-risk opportunity with significant upside potential if profitability targets are met. The stock faces execution risks in African e-commerce expansion and persistent negative cash flow, but strong revenue growth and analyst support suggest potential for recovery if the 2027 breakeven timeline is achieved.
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
